Quest Introduces Myeloma Test That Eliminates the Need for Bone Marrow Biopsies
The flow cytometry assay costs a fraction of traditional invasive bone marrow testing
Keeps You Up-to-Date on New Diagnostic Tests, Testing Trends and Opportunities, and Emerging Test Technologies
The flow cytometry assay costs a fraction of traditional invasive bone marrow testing
From - Diagnostic Testing & Emerging Technologies
Women who do not meet breast cancer genetic testing criteria have a similar number of cancer-associated mutations as women who do meet the criteria…
From - Diagnostic Testing & Emerging Technologies
Screening the entire U.S. blood supply for Zika virus may not be worth the $42 million price tag. Fifteen months of screening all…
From - Diagnostic Testing & Emerging Technologies
A genetic risk score (GRS) may identify patients at highest risk for developing atrial fibrillation (AF), according to a study published…
From - Diagnostic Testing & Emerging Technologies
The FY 2018 omnibus appropriations bill, passed by Congress in late March, included a little noticed provision that could ultimately bring significant changes to the laboratory industry…
From - Diagnostic Testing & Emerging Technologies
Raw data from direct-to-consumer (DTC) genetic tests have an "alarmingly high" false-positive rate, according to a study published…